Favorable Gi Profile of Celecoxib Vs Nsnsaids Based on Pooled Analysis of 21 Celecoxib Randomized Controlled Trials

Liviu Niculescu,Chunming Li,Jim Huang,Sharon Mallen

DOI: https://doi.org/10.14309/00000434-200809001-00998

2008-01-01

Abstract:Purpose: To compare the gastrointestinal (GI) tolerability of celecoxib with that of nonselective (ns) NSAIDs in patients with osteoarthritis (OA), adult rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Randomized, controlled trials from the Pfizer Corporate Clinical Trials Registry, available as of October 31, 2004 were selected using the following criteria: (1) Parallel-group study design and planned treatment duration of ≥2 weeks (2) At least one nsNSAID (naproxen, ibuprofen or diclofenac) as a comparator (3) At least one arm with 200 mg or 400 mg celecoxib per day. Data was pooled by treatment and by subject from the safety analysis population of each included study. The primary end point of the analysis was the combined incidence of tolerability-related GI adverse events (AEs) (abdominal pain, dyspepsia, nausea, diarrhea and flatulence). The secondary endpoints included the incidence of all AEs, incidence of GI AEs, and time to study discontinuation due to GI AEs and due to GI tolerability AEs. Results: Twenty-one studies involving 23,545 patients (mean age [SE] 60.7 (0.1) years) met the selection criteria. In total 85.9%, 12.1% and 1.9% of patients were treated for OA, RA and AS, respectively, with a mean (median) treatment exposure of 0.21 (0.2) years. Most patients were female (72.6%) and Caucasian (72.7%). The table shows the incidence of AEs, GI AEs, and GI tolerability AEs. Significantly more patients treated with each nsNSAID than with celecoxib experienced a tolerability-related GI AE, or a general GI AE (each comparison: P < 0.0001 vs each nsNSAID). Starting at week one, significantly fewer patients treated with celecoxib discontinued treatment due to GI AEs compared with those treated with naproxen (1.7% vs 3.7%P < 0.0001). The difference in discontinuations due to GI AEs for celecoxib versus ibuprofen and versus diclofenac reached statistical significance at week 4 (vs ibuprofen 3.1% vs 5%P= 0.0156; vs diclofenac 3.1% vs 3.7%P= 0.0314). The time to discontinuation due to a tolerability-related GI AE followed a similar pattern. Conclusion: In this pooled analysis, OA, RA and AS patients treated with celecoxib had fewer GI tolerability-related AEs. Celecoxib treated patients also had fewer GI AEs and fewer discontinuations due to GI AEs and GI tolerability AEs than patients treated with naproxen, ibuprofen or diclofenac.Table: Incidence of GI AEs.